Scott Brun - Articles and news items

AbbVie Logo

AbbVie submits for EU marketing authorization its investigational, all-oral, interferon-free therapy for the treatment of chronic hepatitis C

Industry news / 8 May 2014 / AbbVie

AbbVie submitted marketing authorization applications to the European Medicines Agency seeking approval for the company’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus infection…

AbbVie Logo

Abbvie announces initiation of pivotal Phase III study of veliparib (abt-888) for patients with non-small cell lung cancer

Industry news / 15 April 2014 / AbbVie

AbbVie announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib…

AbbVie Logo

Abbvie completes largest phase iii program of an all-oral, interferon-free therapy for the treatment of hepatitis c genotype 1

Industry news / 31 January 2014 / AbbVie

AbbVie announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie’s investigational all-oral, interferon-free therapy…

AbbVie Logo

AbbVie releases first of six phase III results from investigational all-oral, interferon-free, 12-week regimen, showing 96% SVR12 in Genotype 1 hepatitis C patients new to therapy

Industry news / 18 November 2013 / AbbVie

AbbVie’s multinational HCV program is the largest all-oral, interferon-free clinical program in GT1 patients being conducted to date…

Abbott logo

Abbott announces Phase 3 hepatitis C program details

Industry news, News / 13 November 2012 / Abbott

Details on its phase 3 hepatitis C registrational program…

Abbott logo


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...